Pliant Therapeutics (NASDAQ:PLRX) Hits New 1-Year Low at $11.91

Pliant Therapeutics, Inc. (NASDAQ:PLRX) reached a new 52-week low on Wednesday . The stock traded as low as $11.91 and last traded at $11.91, with a volume of 159953 shares. The stock had previously closed at $12.52.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Pliant Therapeutics in a research report on Wednesday, April 10th. Royal Bank of Canada raised their target price on Pliant Therapeutics from $50.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, March 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $48.00 price target on shares of Pliant Therapeutics in a research report on Wednesday, February 28th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $49.00.

Pliant Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 17.72 and a current ratio of 17.72. The company has a market cap of $716.86 million, a price-to-earnings ratio of -4.33 and a beta of 1.12. The firm’s 50-day moving average price is $15.00 and its 200 day moving average price is $15.59.

Hedge Funds Weigh In On Pliant Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in PLRX. Barclays PLC lifted its position in Pliant Therapeutics by 165.3% in the 3rd quarter. Barclays PLC now owns 244,266 shares of the company’s stock valued at $4,236,000 after acquiring an additional 152,190 shares in the last quarter. UBS Group AG raised its position in Pliant Therapeutics by 8,855.2% in the 3rd quarter. UBS Group AG now owns 270,804 shares of the company’s stock valued at $4,696,000 after buying an additional 267,780 shares during the last quarter. Silverarc Capital Management LLC lifted its stake in Pliant Therapeutics by 133.4% in the 3rd quarter. Silverarc Capital Management LLC now owns 250,409 shares of the company’s stock valued at $4,342,000 after acquiring an additional 143,142 shares in the last quarter. Profund Advisors LLC bought a new position in shares of Pliant Therapeutics during the 3rd quarter worth approximately $215,000. Finally, Corton Capital Inc. acquired a new stake in shares of Pliant Therapeutics in the third quarter valued at approximately $197,000. Institutional investors and hedge funds own 97.30% of the company’s stock.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.